Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Jesse Selnick Biography and Net Worth

CFO of Sight Sciences

Selnick brings to Sight Sciences more than 20 years of experience leading strategic growth, financing, capital allocation and operational initiatives for companies. Most recently as CFO of Electric Lightwave, an over $500 million revenue business, Selnick led an approximately 100-person team responsible for corporate strategy, M&A, capital planning, treasury, accounting and tax, financial planning and analysis, business development, real estate and risk management. Since 2011, Selnick has served as a General Partner of Sight Sciences Angels, LP (SSA), one of the founding investors in Sight Sciences. SSA’s limited partnership group is comprised of leading private equity and hedge fund investors, corporate executives and investment bankers who have invested individually in Sight Sciences through SSA. Earlier in his career, Selnick served as a Managing Director at The Blackstone Group for approximately 10 years in its mergers and acquisitions advisory practice. Selnick holds a B.S. in Economics from The Wharton School at The University of Pennsylvania and an M.B.A. from Harvard Business School.

How do I contact Jesse Selnick?: The corporate mailing address for Mr. Selnick and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on Jesse Selnick's contact information.
Has Jesse Selnick been buying or selling shares of Sight Sciences?: Jesse Selnick has not been actively trading shares of Sight Sciences within the last three months. Most recently, on Tuesday, November 23rd, Jesse Selnick bought 10,000 shares of Sight Sciences stock. The stock was acquired at an average cost of $18.44 per share, with a total value of $184,400.00. Learn More on Jesse Selnick's trading history.
Who are Sight Sciences' active insiders?: Sight Sciences' insider roster includes Staffan Encrantz (Director), and Jesse Selnick (CFO). Learn More on Sight Sciences' active insiders.
Are insiders buying or selling shares of Sight Sciences?: In the last year, Sight Sciences insiders bought shares 7 times. They purchased a total of 521,854 shares worth more than $1,459,475.22. In the last year, insiders at the sold shares 10 times. They sold a total of 2,915,477 shares worth more than $17,037,556.20. The most recent insider tranaction occured on April, 3rd when insider Jeremy B Hayden sold 4,893 shares worth more than $24,856.44. Insiders at Sight Sciences own 27.1% of the company. Learn More about insider trades at Sight Sciences.
Information on this page was last updated on 4/3/2024.

Jesse Selnick Insider Trading History at Sight Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/23/2021	Buy	10,000	$18.44	$184,400.00

Jesse Selnick Buying and Selling Activity at Sight Sciences

Sight Sciences Company Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Today's Range

Now: $5.13

$5.00

$5.45

50 Day Range

MA: $4.84

$4.02

$6.10

2 Week Range

Now: $5.13

$1.04

$11.20

Volume

134,675 shs

Average Volume

224,567 shs

Market Capitalization

$254.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.83